Literature DB >> 14701871

Opportunities and challenges in the development of kinase inhibitor therapy for cancer.

Charles L Sawyers1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14701871     DOI： 10.1101/gad.1152403

Source DB:  PubMed          Journal:  Genes Dev        ISSN： 0890-9369            Impact factor:   11.361


× No keyword cloud information.
  34 in total

1.  Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells.

Authors:  Geoffrey A Bartholomeusz; Moshe Talpaz; Vaibhav Kapuria; Ling Yuan Kong; Shimei Wang; Zeev Estrov; Waldemar Priebe; Ji Wu; Nicholas J Donato
Journal:  Blood       Date:  2007-01-03       Impact factor: 22.113

Review 2.  Target validation to biomarker development: focus on RNA interference.

Authors:  Riccardo Colombo; Jürgen Moll
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

3.  New class of competitive inhibitor of bacterial histidine kinases.

Authors:  Raymond Gilmour; J Estelle Foster; Qin Sheng; Jonathan R McClain; Anna Riley; Pei-Ming Sun; Wai-Leung Ng; Dalai Yan; Thalia I Nicas; Kenneth Henry; Malcolm E Winkler
Journal:  J Bacteriol       Date:  2005-12       Impact factor: 3.490

4.  Response to erlotinib in recurrent glioblastoma multiforme showing coexpression of EGFRvIII and PTEN.

Authors:  A Custodio; A Calles; P Pérez-Segura
Journal:  Clin Transl Oncol       Date:  2010-04       Impact factor: 3.405

5.  A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance.

Authors:  Kiranmai Gumireddy; Stacey J Baker; Stephen C Cosenza; Premila John; Anthony D Kang; Kimberly A Robell; M V Ramana Reddy; E Premkumar Reddy
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-27       Impact factor: 11.205

Review 6.  Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies.

Authors:  Giampaolo Tortora; Roberto Bianco; Gennaro Daniele; Fortunato Ciardiello; James A McCubrey; Maria Rosaria Ricciardi; Ludovica Ciuffreda; Francesco Cognetti; Agostino Tafuri; Michele Milella
Journal:  Drug Resist Updat       Date:  2007-05-07       Impact factor: 18.500

7.  AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).

Authors:  Patrick P Zarrinkar; Ruwanthi N Gunawardane; Merryl D Cramer; Michael F Gardner; Daniel Brigham; Barbara Belli; Mazen W Karaman; Keith W Pratz; Gabriel Pallares; Qi Chao; Kelly G Sprankle; Hitesh K Patel; Mark Levis; Robert C Armstrong; Joyce James; Shripad S Bhagwat
Journal:  Blood       Date:  2009-08-04       Impact factor: 22.113

8.  A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition.

Authors:  Neil E Torbett; Antonio Luna-Moran; Zachary A Knight; Andrew Houk; Mark Moasser; William Weiss; Kevan M Shokat; David Stokoe
Journal:  Biochem J       Date:  2008-10-01       Impact factor: 3.857

9.  Discovery of cercosporamide, a known antifungal natural product, as a selective Pkc1 kinase inhibitor through high-throughput screening.

Authors:  Andrea Sussman; Karen Huss; Li-Chun Chio; Steve Heidler; Margaret Shaw; Doreen Ma; Guoxin Zhu; Robert M Campbell; Tae-Sik Park; Palaniappan Kulanthaivel; John E Scott; John W Carpenter; Mark A Strege; Matthew D Belvo; James R Swartling; Anthony Fischl; Wu-Kuang Yeh; Chuan Shih; Xiang S Ye
Journal:  Eukaryot Cell       Date:  2004-08

10.  Sequence and structure signatures of cancer mutation hotspots in protein kinases.

Authors:  Anshuman Dixit; Lin Yi; Ragul Gowthaman; Ali Torkamani; Nicholas J Schork; Gennady M Verkhivker
Journal:  PLoS One       Date:  2009-10-16       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.